For the Inventor, By the Inventor

Enter assignee name

Philadelphia, PA, United States of America

Amicus Therapeutics, Inc.

USPTO Granted Patents = 157

CIPO Patents = 12

EPO Patents = 65

Trademarks = 18

Forward Citations = 1,992

Loading Chart...

Loading Chart...

56 inventors (with patents filed for the assignee):

Jeff Castelli (57 out of 57 patents)

Elfrida Benjamin (56 out of 56 patents)

Hung V Do (31 out of 31 patents)

4. Robert E Boyd (19 out of 32 patents)

5. Russell Gotschall (15 out of 15 patents)

6. Brandon Alan Wustman (15 out of 19 patents)

7. Richie Khanna (14 out of 14 patents)

8. Gary Lee (14 out of 15 patents)

9. David J Lockhart (14 out of 60 patents)

10. Kenneth Valenzano (13 out of 13 patents)

11. Philip J Rybczynski (12 out of 32 patents)

12. Kamlesh A Sheth (12 out of 12 patents)

13. John R Flanagan (11 out of 139 patents)

14. Sergey Tesler (7 out of 7 patents)

15. John Crowley (6 out of 6 patents)

Core Competencies:

Pompe Disease

Fabry Disease

Alpha-Glucosidase

Migalastat

Gene Therapy

Recombinant Proteins

Pharmaceutical Compositions

Lysosomal Storage Disorders

Drug Formulations

Renal Impairment

Disulfide Bond Stabilization

Central Nervous System Disorders

157 patents: Sort by Forward Citations

1. 12419937 - High concentration alpha-glucosidase compositions for the treatment of Pompe disease (2025-09-23),

2. 12414985 - Augmented acid alpha-glucosidase for the treatment of Pompe disease (2025-09-16),

3. 12414944 - Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene (2025-09-16),

4. D1087752 - Drug package (2025-08-12),

5. D1082532 - Drug package (2025-07-08),

6. 12280042 - Methods of treating fabry patients having renal impairment (2025-04-21),

7. 12275703 - Highly purified batches of pharmaceutical grade migalastat and methods of producing the same (2025-04-14),

8. 12246062 - Recombinant human acid alpha-glucosidase (2025-03-11),

9. 12109205 - Methods of treating Fabry patients having renal impairment (2024-10-08),

10. 12070453 - Treatment of Fabry disease in ERT-naïve and ERT-experienced patients (2024-08-27),

11. 12064485 - Disulfide bond stabilized polypeptide compositions and methods of use (2024-08-20),

12. 12042490 - Methods of treating Fabry patients having renal impairment (2024-07-23),

13. 12042489 - Methods of treating Fabry patients having renal impairment (2024-07-23),

14. 12042488 - Methods of treating Fabry patients having renal impairment (2024-07-23),

15. 11903938 - Methods of treating Fabry patients having renal impairment (2024-02-20),

Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing, and delivering novel medicines for people living with rare diseases. With a patient-centric approach, Amicus aims to develop innovative therapies to address significant unmet medical needs. The company's research and development efforts are directed towards a range of genetic diseases, including lysosomal storage disorders and muscular dystrophies. Amicus is committed to potentially transforming the lives of patients and their families through pioneering treatments.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

157 Patents

#17 in Philadelphia, PA

#103 in Pennsylvania

#2,444 in US

#5,110 in the World

Philadelphia, PA, United States of America

Amicus Therapeutics, Inc.

Forward Citations = 1,992

56 inventors:

Jeff Castelli (57 out of 57 patents)

Elfrida Benjamin (56 out of 56 patents)

Hung V Do (31 out of 31 patents)

4. Robert E Boyd (19 out of 32 patents)

5. Russell Gotschall (15 out of 15 patents)

Please report any incorrect information to support@idiyas.com

Loading…